ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C4H3FN2O2
CAS番号:
分子量:
130.08
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
127172
製品名
5-フルオロウラシル, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
SMILES string
FC1=CNC(=O)NC1=O
InChI key
GHASVSINZRGABV-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
fluorouracil
manufacturer/tradename
USP
mp
282-286 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... TYMS(7298)
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Fluorouracil USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Flucytosine
- Flucytosine Capsules
- Fluorouracil
- Fluorouracil Cream
- Fluorouracil Injection
- Fluorouracil Topical Solution
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Carc. 2
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Zhe Guo et al.
Annals of surgical oncology, 21(9), 3069-3076 (2014-04-15)
It is unclear whether hepatic resection (HR) or transarterial chemoembolization (TACE) is associated with better outcomes for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage A. The present study compared survival for patients with BCLC stage
Tania Diaz et al.
Journal of surgical oncology, 109(7), 676-683 (2014-02-11)
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from
John M L Ebos et al.
EMBO molecular medicine, 6(12), 1561-1576 (2014-11-02)
Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and
Sharlene Gill et al.
Cancer treatment reviews, 40(10), 1171-1181 (2014-12-03)
Colorectal cancer (CRC) is the third most commonly diagnosed cancer among males and second among females worldwide. The treatment landscape for advanced CRC (aCRC) is rapidly evolving and there are now a number of randomized trials assessing treatment of aCRC
Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer.
Steven R Alberts et al.
PharmacoEconomics, 32(12), 1231-1243 (2014-08-27)
Prior economic analysis that compared the 12-gene assay to published patterns of care predicted the assay would improve outcomes while lowering medical costs for stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer patients. This study assessed the validity of those findings
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）